Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Glomerular Diseases: Update for the Clinician
Open Access

Viral-Associated GN: Hepatitis B and Other Viral Infections

Warren L. Kupin
CJASN September 2017, 12 (9) 1529-1533; DOI: https://doi.org/10.2215/CJN.09180816
Warren L. Kupin
Division of Nephrology, Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

By definition, viral-associated GN indicates the direct pathogenic relationship between active viral replication and the development of acute GN. This definition is in sharp contrast to the semantic label and pathophysiologic foundation behind postinfectious GN that uniquely develops only during a period of resolved and absent active infection. The primary example of postinfectious GN are the glomerular lesions described after a pharyngeal or cutaneous streptococcal infection and do not represent the clinical or immunologic pattern seen with viral-associated GN. Hepatitis B (HBV) is the most common chronic viral infection in the world affecting >400 million people which is more than double the prevalence of chronic HIV and hepatitis C carriers combined. In addition, 10%–20% of HBV patients may be coinfected with hepatitis C and 5%–10% will have coinfection with HIV. Being able to distinguish the different types of GN seen with each viral infection is essential for the practicing clinician as each virus requires its own specific antiviral therapy. HBV-induced immune complex disease with renal injury lies on one end of the spectrum of disorders that occurs after a prolonged chronic carrier state. On the opposite end of the spectrum are renal diseases that develop from acute or subacute viral infections. One important glomerular lesion in this category is the association of collapsing FSGS with acute active cytomegalovirus, Epstein–Barr virus, and parvovirus B19 infection. The data supporting or disproving this relationship for each of these viruses will be discussed. A second renal manifestation of acute viral infections often occurs with many different sporadic or epidemic infections such as dengue and hantavirus and can lead to a transient proliferative GN that resolves upon viral clearance. The complex interplay of HBV and all viruses with the immune system provides conceptual lessons on the pathophysiology of immune complex GN that can be applied to all infection-related renal disease and plays an integral role in developing an approach to therapeutic intervention.

  • Viral-Associated Glomerulonephritis
  • Hepatitis B virus
  • glomerular disease
  • Antigen-Antibody Complex
  • Antiviral Agents
  • Carrier State
  • Coinfection
  • cytomegalovirus
  • Dengue
  • glomerulonephritis
  • HIV Infections
  • Hantavirus
  • Hepatitis C
  • Herpesvirus 4
  • Human
  • Humans
  • Immune Complex Diseases
  • Immune System
  • Parvovirus
  • Prevalence
  • Semantics
  • Streptococcal Infections

Introduction

This issue represents part 2 of the series on viral-associated GN. Part 1 covered the pathophysiology, histopathology, and clinical manifestations of the unique glomerular syndromes seen in those patients with actively replicating chronic hepatitis C (HCV) and HIV infection. In this issue, the focus is on both the glomerular manifestations seen in conjunction with a chronic hepatitis B (HBV) carrier state as well as the individual types of glomerular lesions seen with a variety of acute and subacute viral infections including cytomegalovirus (CMV), parvovirus, Epstein–Barr virus (EBV), hantavirus, and dengue.

Many reviews have listed virus-associated GN syndromes as a subset of the category called postinfectious GN (PIGN) (1,2). This classification is not mechanistically accurate because PIGN is associated with the characteristic sequence of a latent time period from a completely resolved infection followed by an acute immune complex–mediated GN. This is in distinct contrast to viral-associated GN which occurs exclusively in the setting of an active replicating viral infection and resolves with eradication of the viremic state. In this scenario, there is no onset of renal disease that follows a latent period of absent or resolved infection.

A new proposal for classification of the category, infection-related GN, centers on eliminating the term PIGN because the only proven infection that causes the clinical pattern of active infection – resolved infection – latent period– acute GN is streptococcal disease. Therefore, the term poststreptococcal GN (PSGN) should replace the use of the general term PIGN because no other infections fit into that category.

All other infection-related glomerular diseases are considered separate and distinct from PSGN and the term “associated” is used to delineate the coexistent dependent relationship between active replicating infection and renal disease whether the infection is bacterial, fungal, protozoal, or viral (3,4).

Virus-associated GN syndromes do not share a final common pathway of renal injury but do share the theme of an acute, subacute, or chronically active viral infection as the core foundation for their nephrotoxicity. By using this new classification on the basis of pathophysiology it is clear why antibiotic therapy is ineffective for PSGN and the key therapy for infection/viral-associated GN.

HBV

A true global pandemic, chronic HBV antigenemia, defined as persistent circulating hepatitis B surface antigen (HBsAg), is present in 240 million people worldwide, representing 5%–6% of the world population. Approximately 2 million people in the United States are chronic HBV carriers with 20,000–40,000 new cases of HBV exposure occurring yearly (5).

Overall, renal disease may occur in 3%–5% of patients with chronic HBV infection (6). The histologic manifestations of HBV-associated renal disease can be classified as those that occur as a result of either (1) immune-complex GN (membranous [membranoproliferative GN (MPGN)] and IgA nephropathy) or (2) immune complex–related vasculitis (polyarteritis nodosa [PAN]) (Figure 1). It is important to note that many patients with chronic HBV may also harbor coexistent HIV (5%–10%) and HCV (10%–30%) that may dictate the glomerular pathology expressed and further broaden the clinical differential diagnosis (7). Checking for these other latent viruses in all HBV carriers is essential during the evaluation process.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Glomerular syndromes associated with an HBV carrier state. MC, mixed cryoglobulinemia; MN, membranous glomerulopathy; MPGN, membranoproliferative GN; PAN, polyarteritis nodosa.

Membranous Nephropathy

The histologic appearance of HBV membranous nephropathy (MN) is indistinguishable from idiopathic MN with clearly defined subepithelial immune complex deposits on electron microscopy. The antigen within the immune deposits in HBV-related MN may arise from three potential viral particles: HBsAg, HBcAg, or the HBeAg (8). In addition, from a mechanistic standpoint, the deposits may form from either deposition of an IgG immune complex with one or more of the stated antigens or with the de novo formation of an immune complex after deposition of the circulating antigen in the basement membrane first followed afterward by deposition of the circulating antibody. The size and charge of the antigens are an important determinant of their pathogenicity and ability to traverse across the glomerular basement membrane. The HBeAg is the smallest of the three antigens at 17 kD, with HBsAg measuring 35–50 kD and HBcAg at 22 kD. Approximately 90% of patients with chronic HBV and biopsy-proven MN have detectable HBeAg isolated from the glomerulus and >95% of these patients have measurable circulating HBeAg. IgG-HBeAg complexes tend to be cationic enhancing their deposition in the subepithelial space compared with the anionic IgG-HBsAg complexes which are more restricted to the subendothelial space (9).

In addition, acquired missense nucleotide mutations of the HBV x gene in specific locations (C1653T, A1726C, A1727T, C1730G, T1753C, A1762T, and G1764A) were found in 84% of patients with MN and in only 8% of control patients, which may explain the predisposition of certain HBV carriers to develop renal disease (10). Of the eight genotypes of HBV, genotype A appears to have the highest risk of MN or MPGN.

It has been suggested that idiopathic MN can be differentiated from HBV-associated MN by the presence of circulating anti-phospholipase A2 receptor antibodies (anti-PLA2R) and by the characterization of the IgG subtype in the glomerular basement membrane as IgG4 (11). In HBV-associated MN the IgG subtype tends to be predominantly of the IgG1 class.

Although initial reports showed <5% of patients with HBV-associated MN having a positive assay for anti-PLA2R (12), a recent study indicated contradictory findings with 64% of HBV patients showing anti-PLA2R (13). The study also demonstrated the presence of HBV antigens colocalizing with anti-PLA2R antibody confirming the possible association of these two findings. Therefore, the utility of anti-PLA2R in separating idiopathic MN from HBV-related MN is not clearly substantiated at the present time.

Tubular reticular inclusions have been frequently reported in Systemic Lupus Erythematosis and HIV renal disease but have now also been described in MN associated with HBV and even in HCV glomerular lesions (14). The renal presence of tubular reticular inclusions then appears to confirm the local upregulation of IFN which any significant viral illness may stimulate and identifying their presence makes the diagnosis of MN less likely idiopathic in origin and more likely secondary to an autoimmune or infectious origin.

Progression of HBV-related MN toward ESRD occurs in approximately 25%–35% of adults compared with a rate of <5% in children (15). Spontaneous biopsy-proven histologic resolution of MN has been shown in children which has been associated with systemic HBeAg clearance by the age of 4 years (16).

MPGN

MPGN represents the second most common renal glomerular syndrome in HBV carriers after MN in both adults and children and is characterized by the typical lobular appearance of the glomerulus with splitting of the basement membrane and mesangial, subendothelial, and even subepithelial deposits. The typical glomerular antigen deposited is the HBsAg due to its size restriction with IgG to the subendothelial space (17). Both type 1 and type 3 MPGN have been described in chronic HBV carriers. The clinical presentation is similar to patients with idiopathic MPGN and is characterized by the nephritic syndrome with or without nephrotic range proteinuria and decreased levels of serum C primarily in the classic pathway (low C3 and C4) (8).

Recently reported as an additional cause of type 1 MPGN in HBV carriers is mixed cryoglobulinemia. The majority of these patients (75%) presented after >10 years of HBV infection with predominantly type 3 cryoglobulinemia (polyclonal IgM – polyclonal IgG). This compares to a greater propensity (80%) of type 2 cryoglobulinemia (monoclonal IgM – polyclonal IgG) with type 1 MPGN in chronic HCV infection of >10–15 years (18). HBV patients with cryoglobulinemia may present with nephrotic syndrome, AKI, and systemic vasculitis with low C4 (92%) and low C3 (58%). Because HBV is not lymphotropic, it is not known how HBV induces B cell cryoglobulin production. As a result of this new relationship of HBV and cryoglobulinemia it is essential to exclude coinfection with hepatitis C as a cause of MPGN in HBV carriers because up to 10% of patients worldwide carry both viral infections and the treatment will be dictated by which infection is causing the renal lesion.

Treatment

For HBV patients with MN, Kidney Disease Improving Global Outcomes recommends the use of IFN or oral antiviral agents which consist of either nucleotide (tenofovir, adefovir) or nucleoside (lamivudine, entecavir, telbivudine) reverse transcription inhibitors (19). In the treatment of hepatitis B MN, lamivudine (a cytidine analog) has been the most commonly used agent associated with an initial remission of viremia and complete resolution of the MN lesion in 75%–80% of patients. However, lamivudine is associated with a 20% per year resistance rate as a consequence of a somatic mutation of the HBV reverse transcription gene at the YMDD motif (Y, tyrosine; M, methionine; D, aspartic acid; D, aspartic acid) (20). For this reason, either entecavir or tenofovir have now been recommended as first line therapy as neither drug is associated with clinically relevant acquired resistance (21).

A recent meta-analysis of 13 studies and 325 patients confirmed the clinical safety and renal efficacy of these agents in the treatment of HBV-associated MN. Corticosteroids may be given for a period of <6 months without a significant effect on liver disease, HBV viremia, or patient morbidity or mortality as long as concomitant antiviral therapy is used (22).

The treatment of HBV-related MPGN with type 3 cryoglobulinemia is completely distinct from the treatment of HCV type 2 cryoglobulinemia and focuses on the control of HBV viremia rather than the use of direct-acting antivirals, rituximab, plasmapheresis, and possible cytotoxic therapy as systemic cryoglobulinemic vasculitis is unusual with HBV.

Universal HBV vaccination has been shown to successfully reduce those childhood cases of HBV MN related to horizontal transmission of the virus but will have no effect of HBV MN due to vertical acquisition of HBV which still represents an important transmission vector in third world countries (23).

Additional HBV-Associated Glomerular Lesions

The most common cause of PAN in the 1980s was HBV (>80%) however with global efforts of HBV vaccination, not only has the prevalence of HBV-associated MN in children declined dramatically but so have the number of cases of PAN from HBV (<20% of all cases). PAN in HBV patients is a result of HBsAg antibody immune complexes depositing in medium size blood vessels (24). Compared with idiopathic PAN, HBV patients had a more severe Birmingham Vasculitis Score on presentation, more frequent mesenteric artery aneurysms compared with renal artery involvement, a greater propensity for gastrointestinal vasculitis, less severe skin manifestations, and a more favorable response to therapy with fewer relapses. HBV-associated PAN leads to AKI from renal ischemia and infarction. Therefore, the presence of acute GN should exclude PAN from the differential diagnosis.

HBV viral transcripts have also been noted in patients with IgA nephropathy and are located in renal mesangial cells of patients with FSGS suggesting HBV as a possible etiology of both of these lesions (25). In anecdotal cases, antiviral therapy led to resolution of the glomerular disease substantiating the possible causative role of HBV in a select group of IgA and FSGS patients. In addition, case reports of minimal change (MC) disease in children with HBV who entered into clinical remission strictly after antiviral therapy proposes yet another renal lesion with possible links to chronic HBV viremia (26).

Acute and Subacute Viral-Induced GN

Although any acute viral illness can lead to an immune complex–proliferative GN, a select group of viral syndromes deserve special consideration for the way in which they induce glomerular injury: dengue, hantavirus, and the group of non-HIV viruses that have been associated with collapsing FSGS (cFSGS) (parvovirus, EBV, and cytomegalovirus).

Dengue is truly a worldwide infection with 40% of the global population living in endemic areas especially Latin America, Southeast Asia, and the Pacific Islands. An estimated 100 million new infections occur each year through the bite primarily of the female mosquito Aedes aegyptii. Dengue is classified into specific syndromes: dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. AKI is found in approximately 10%–14% of patients and is primarily seen in dengue hemorrhagic fever and dengue shock syndrome and results from acute tubular necrosis (ATN) as a consequence of hypovolemia (capillary leak) and/or rhabdomyolysis (27).

GN in dengue is now well described in animal models and in human infection and results not only from immune complex deposition but also from direct viral entry into renal tissue (28). Predominant mesangial hypercellularity with immune complexes and IgM deposition has been reported with some patients showing diffuse proliferative GN. The presence of hematuria and proteinuria (both non-nephrotic and nephrotic) helps distinguish these cases from typical ATN. Treatment remains supportive in all categories of dengue but the sheer size of the population involved with dengue makes it certain that nephrologists need to be aware of the glomerular manifestations of this infection.

Hantaviruses are RNA viruses that belong to the Bunyaviridae family and enter the population through exposure to rodent urine, saliva, or feces. Consequently, public health programs worldwide are challenged with the responsibility to eliminate the rodent vector from urban and rural population areas (29). Two major syndromes can develop from the 100,000 new cases of hantavirus exposure each year both of which may have associated renal involvement: hanta pulmonary syndrome and hemorrhagic fever with renal syndrome. Hantavirus has recently been implicated as one potential explanation for mesoamerican nephropathy (30).

Hemorrhagic fever with renal syndrome is characterized by diffuse endothelial cell injury as a consequence of direct viral infection (via integrin αvβ3 and CD55) of most cells including renal tissue with resultant capillary leak and intravascular volume depletion leading to ATN. Capillary endothelial cells are similarly affected and podocyte effacement has been demonstrated leading to both nephrotic and nephritic syndromes (31). Complementing the podocyte injury is an extensive interstitial CD8+ T cell infiltrate with a “cytokine storm” that may contribute further to the degree of systemic hypotension and podocyte dysfunction (32). Mesangial proliferative GN with deposits of C3 and IgM and immune complex deposition have been reported. Similar to dengue, no specific therapy is available for hantavirus infection but preventive strategies with widespread vaccination are undergoing clinical trials.

cFSGS

Viral-induced cFSGS has long been associated with parvovirus B19 (33). This relationship has been repeatedly emphasized in the differential diagnosis of cFSGS using in situ hybridization techniques; parvovirus DNA has been identified in renal endothelial and epithelial cells, both visceral and parietal, from patients with a variety of renal diseases including cFSGS (90%), idiopathic FSGS (80%), membranous (50%), and MC disease (50%) (34). Additional investigators have confirmed the ability to identify parvovirus within the podocyte and parietal cells of patients with cFSGS lesions to a greater extent than other renal diseases (35). Clearly, parvovirus proteins appear to remain in the kidney but whether they have any replicative properties that result in podocyte dysfunction is still a matter of significant debate. The final assessment is that in contrast to current accepted dogma the precise link between parvovirus and cFSGS is still circumstantial (36).

CMV like parvovirus and EBV can cause acute immune complex GN especially with vertical transmission and MN has been the most common renal histology reported in this setting (37). In addition, CMV causes a distinct tubulointerstitial nephritis in transplant patients and may play a role in the development of transplant glomerulopathy. Acute CMV infection has also been associated with cFSGS. It has been suggested that the acute local renal IFN response could be responsible for the development of the FSGS lesion as opposed to a direct effect of the virus on the podocyte (38). Interestingly, the data supporting CMV as a cause of cFSGS appears stronger than that of parvovirus.

EBV has been linked to the development of MN in both the acute and subacute setting and in rare circumstances cFSGS (39). EBV viral DNA however has been consistently localized to the renal tubules but rarely has glomerular deposition been demonstrated. Anecdotal cases of MPGN and postinfectious GN have been published but there are too few cases to draw consistent conclusions regarding the pathogenesis. The correlation of cFSGS is the weakest for EBV compared with CMV and parvovirus (40).

Finally, the potential interaction of specific virus infections in a host with APOL1 variants and the long term risk of developing FSGS are being studied (41). At present, the unexpected association of the polyoma JC virus with the development of FSGS has been demonstrated. This data supports the importance of not just looking at the direct influence of a virus itself on podocyte regulation but also on host genetic susceptibility to FSGS that may be magnified by the viral infection.

Viral-Induced De novo and Clinical Relapse of MC Disease

In children there is strong data supporting the role of many different types of viral diseases leading to a relapse of previously diagnosed MC disease. In particular, upper respiratory viral infections have been implicated such as respiratory syncitial virus, influenza, and parainfluenza (42). In addition, new onset varicella infection and the actual mumps/measles/rubella vaccine have been linked to a relapse of nephrotic syndrome from prior MC disease. It is hypothesized that cytokine release as a consequence of the acute viral syndrome may induce foot process effacement and nephrotic proteinuria.

In contrast, a number of series have shown that acute measles infection has led to a temporary remission of MC disease (43). A variety of extrarenal autoimmune syndromes have also been reported to be attenuated temporarily and go into remission with acute measles, including immune thrombocytopenia and hyperimmune globulin E syndrome. An alteration of T suppressor/helper cells during active measles has been suggested as a cause of this downregulation of the immune system and transient remission of MC disease. No consistent effect of the mumps/measles/rubella vaccine has been reported on childhood nephrotic syndrome.

Summary

In the evaluation of patients with GN, the presence of acute or chronic viral infections must be an important part of the differential diagnosis. Familiarity with the different renal syndromes associated with viral diseases is paramount which can then lead to specific diagnostic testing and therapeutic interventions that would not normally have been considered. The study of viral-associated GN has led to a better understanding of the complex interactions of the adaptive immune system, viral antigen–antibody immune complexes, genetic risk factors, and host cytokine responses that all lead to a unique array of renal pathology.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2017 by the American Society of Nephrology

References

  1. ↵
    1. Nast CC
    : Infection-related glomerulonephritis: changing demographics and outcomes. Adv Chronic Kidney Dis 19: 68–75, 2012
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kanjanabuch T,
    2. Kittikowit W,
    3. Eiam-Ong S
    : An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 5: 259–269, 2009
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nadasdy T,
    2. Hebert LA
    : Infection-related glomerulonephritis: understanding mechanisms. Semin Nephrol 31: 369–375, 2011
    OpenUrlCrossRefPubMed
  4. ↵
    1. Glassock RJ,
    2. Alvarado A,
    3. Prosek J,
    4. Hebert C,
    5. Parikh S,
    6. Satoskar A,
    7. Nadasdy T,
    8. Forman J,
    9. Rovin B,
    10. Hebert LA
    : Staphylococcus-related glomerulonephritis and poststreptococcal glomerulonephritis: why defining “post” is important in understanding and treating infection-related glomerulonephritis. Am J Kidney Dis 65: 826–832, 2015
    OpenUrlCrossRefPubMed
  5. ↵
    1. Zampino R,
    2. Boemio A,
    3. Sagnelli C,
    4. Alessio L,
    5. Adinolfi LE,
    6. Sagnelli E,
    7. Coppola N
    : Hepatitis B virus burden in developing countries. World J Gastroenterol 21: 11941–11953, 2015
    OpenUrlCrossRefPubMed
  6. ↵
    1. Gupta A,
    2. Quigg RJ
    : Glomerular Diseases Associated With Hepatitis B and C. Adv Chronic Kidney Dis 22: 343–351, 2015
    OpenUrlCrossRefPubMed
  7. ↵
    1. Basnayake SK,
    2. Easterbrook PJ
    : Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature. J Viral Hepat 23: 545–559, 2016
    OpenUrlCrossRefPubMed
  8. ↵
    1. Li P,
    2. Wei RB,
    3. Tang L,
    4. Wu J,
    5. Zhang XG,
    6. Chen XM
    : Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol 78: 456–464, 2012
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bhimma R,
    2. Coovadia HM
    : Hepatitis B virus-associated nephropathy. Am J Nephrol 24: 198–211, 2004
    OpenUrlCrossRefPubMed
  10. ↵
    1. Hui D,
    2. Yan X,
    3. Wei J,
    4. Ruixia M,
    5. Guangju G
    : Significance of mutations in hepatitis B virus X gene for the pathogenesis of HB-associated glomerulonephritis. Acta Virol 58: 278–281, 2014
    OpenUrlCrossRefPubMed
  11. ↵
    1. Obrisca B,
    2. Ismail G,
    3. Jurubita R,
    4. Baston C,
    5. Andronesi A,
    6. Mircescu G
    : Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. Biomed Res Int 2015: 249740, 2015
  12. ↵
    1. Beck LH Jr.,
    2. Bonegio RGB,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
    OpenUrlCrossRefPubMed
  13. ↵
    1. Xie Q,
    2. Li Y,
    3. Xue J,
    4. Xiong Z,
    5. Wang L,
    6. Sun Z,
    7. Ren Y,
    8. Zhu X,
    9. Hao CM
    : Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 41: 345–353, 2015
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lee CJ,
    2. Suh KS,
    3. Kim KH,
    4. Chang YK,
    5. Na KR,
    6. Lee KW
    : The clinicopathologic significance of endothelial tubuloreticular inclusions in glomerular diseases. Ultrastruct Pathol 37: 386–394, 2013
    OpenUrlCrossRefPubMed
  15. ↵
    1. Ozdamar SO,
    2. Gucer S,
    3. Tinaztepe K
    : Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children. Pediatr Nephrol 18: 23–8, 2003
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hsu HC,
    2. Wu CY,
    3. Lin CY,
    4. Lin GJ,
    5. Chen CH,
    6. Huang FY
    : Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg) carrier children in Taiwan. Kidney Int 36: 1103–1107, 1989
    OpenUrlCrossRefPubMed
  17. ↵
    1. Venkataseshan VS,
    2. Lieberman K,
    3. Kim DU,
    4. Thung SN,
    5. Dikman S,
    6. D’Agati V,
    7. Susin M,
    8. Valderrama E,
    9. Gauthier B,
    10. Prakash A,
    11. Churg J
    : Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore) 69: 200–216, 1990
    OpenUrlCrossRefPubMed
  18. ↵
    1. Li SJ,
    2. Xu ST,
    3. Chen HP,
    4. Zhang MC,
    5. Xu F,
    6. Cheng SQ,
    7. Liu ZH
    : Clinical and Morphologic Spectrum of Renal Involvement in Patients with HBV-Associated Cryoglobulinemia [published online ahead of print April 7, 2016]. Nephrology (Carlton) doi:10.1111/nep.12795, 2016
  19. ↵
    KDIGO Glomerulonephritis Work Group: Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 200–208, 2012
    OpenUrlCrossRefPubMed
  20. ↵
    1. Tipples GA,
    2. Ma MM,
    3. Fischer KP,
    4. Bain VG,
    5. Kneteman NM,
    6. Tyrrell DL
    : Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24: 714–717, 1996
    OpenUrlPubMed
  21. ↵
    1. Elewa U,
    2. Sandri AM,
    3. Kim WR,
    4. Fervenza FC
    : Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 119: c41–c49, discussion c49, 2011
    OpenUrlCrossRefPubMed
  22. ↵
    1. Zheng XY,
    2. Wei RB,
    3. Tang L,
    4. Li P,
    5. Zheng XD
    : Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 18: 821–832, 2012
    OpenUrlCrossRefPubMed
  23. ↵
    1. Liao MT,
    2. Chang MH,
    3. Lin FG,
    4. Tsai IJ,
    5. Chang YW,
    6. Tsau YK
    : Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 128: e600–e604, 2011
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Sharma A,
    2. Sharma K
    : Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis. J Clin Exp Hepatol 3: 204–212, 2013
    OpenUrlCrossRefPubMed
  25. ↵
    1. Sun IO,
    2. Hong YA,
    3. Park HS,
    4. Choi SR,
    5. Chung BH,
    6. Park CW,
    7. Yang CW,
    8. Kim YS,
    9. Choi BS
    : Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail 35: 446–451, 2013
    OpenUrlCrossRefPubMed
  26. ↵
    1. Zhou TB,
    2. Jiang ZP
    : Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail 37: 459–461, 2015
    OpenUrlCrossRefPubMed
  27. ↵
    1. Mallhi TH,
    2. Sarriff A,
    3. Adnan AS,
    4. Khan YH,
    5. Hamzah AA,
    6. Jummaat F,
    7. Khan AH
    : Dengue-induced Acute Kidney Injury (DAKI): A Neglected and Fatal Complication of Dengue Viral Infection--A Systematic Review. J Coll Physicians Surg Pak 25: 828–834, 2015
    OpenUrlPubMed
  28. ↵
    1. Lizarraga KJ,
    2. Nayer A
    : Dengue-associated kidney disease. J Nephropathol 3: 57–62, 2014
    OpenUrlPubMed
  29. ↵
    1. Kruger DH,
    2. Figueiredo LT,
    3. Song JW,
    4. Klempa B
    : Hantaviruses--globally emerging pathogens. J Clin Virol 64: 128–136, 2015
    OpenUrlCrossRefPubMed
  30. ↵
    1. Murray KO,
    2. Fischer RS,
    3. Chavarria D,
    4. Duttmann C,
    5. Garcia MN,
    6. Gorchakov R,
    7. Hotez PJ,
    8. Jiron W,
    9. Leibler JH,
    10. Lopez JE,
    11. Mandayam S,
    12. Marin A,
    13. Sheleby J
    : Mesoamerican nephropathy: a neglected tropical disease with an infectious etiology? Microbes Infect 17: 671–675, 2015
    OpenUrlCrossRefPubMed
  31. ↵
    1. Boehlke C,
    2. Hartleben B,
    3. Huber TB,
    4. Hopfer H,
    5. Walz G,
    6. Neumann-Haefelin E
    : Hantavirus infection with severe proteinuria and podocyte foot-process effacement. Am J Kidney Dis 64: 452–456, 2014
    OpenUrlCrossRefPubMed
  32. ↵
    1. Jiang H,
    2. Du H,
    3. Wang LM,
    4. Wang PZ,
    5. Bai XF
    : Hemorrhagic Fever with Renal Syndrome: Pathogenesis and Clinical Picture. Front Cell Infect Microbiol 6: 1, 2016
    OpenUrlCrossRefPubMed
  33. ↵
    1. Chandra P,
    2. Kopp JB
    : Viruses and collapsing glomerulopathy: a brief critical review. Clin Kidney J 6: 1–5, 2013
    OpenUrlCrossRefPubMed
  34. ↵
    1. di Belgiojoso GB,
    2. Ferrario F,
    3. Landriani N
    : Virus-related glomerular diseases: histological and clinical aspects. J Nephrol 15: 469–479, 2002
    OpenUrlPubMed
  35. ↵
    1. Tanawattanacharoen S,
    2. Falk RJ,
    3. Jennette JC,
    4. Kopp JB
    : Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 35: 1166–1174, 2000
    OpenUrlCrossRefPubMed
  36. ↵
    1. Schwimmer JA,
    2. Markowitz GS,
    3. Valeri A,
    4. Appel GB
    : Collapsing glomerulopathy. Semin Nephrol 23: 209–218, 2003
    OpenUrlCrossRefPubMed
  37. ↵
    1. Beneck D,
    2. Greco MA,
    3. Feiner HD
    : Glomerulonephritis in congenital cytomegalic inclusion disease. Hum Pathol 17: 1054–1059, 1986
    OpenUrlCrossRefPubMed
  38. ↵
    1. Dettmar AK,
    2. Oh J
    : Infection-Related Focal Segmental Glomerulosclerosis in Children. BioMed Res Int 2016:7351964, 2016
  39. ↵
    1. Araya CE,
    2. González-Peralta RP,
    3. Skoda-Smith S,
    4. Dharnidharka VR
    : Systemic Epstein-Barr virus infection associated with membranous nephropathy in children. Clin Nephrol 65: 160–164, 2006
    OpenUrlPubMed
  40. ↵
    1. Joshi A,
    2. Arora A,
    3. Cimbaluk D,
    4. Dunea G,
    5. Hart P
    : Acute Epstein-Barr virus infection-associated collapsing glomerulopathy. Clin Kidney J 5: 320–322, 2012
    OpenUrlCrossRefPubMed
  41. ↵
    1. Divers J,
    2. Núñez M,
    3. High KP,
    4. Murea M,
    5. Rocco MV,
    6. Ma L,
    7. Bowden DW,
    8. Hicks PJ,
    9. Spainhour M,
    10. Ornelles DA,
    11. Kleiboeker SB,
    12. Duncan K,
    13. Langefeld CD,
    14. Turner J,
    15. Freedman BI
    : JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 84: 1207–1213, 2013
    OpenUrlCrossRefPubMed
  42. ↵
    1. MacDonald NE,
    2. Wolfish N,
    3. McLaine P,
    4. Phipps P,
    5. Rossier E
    : Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 108: 378–382, 1986
    OpenUrlCrossRefPubMed
  43. ↵
    1. Wenderfer SE
    : Viral-associated glomerulopathies in children. Pediatr Nephrol 30: 1929–1938, 2015
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 12 (9)
Clinical Journal of the American Society of Nephrology
Vol. 12, Issue 9
September 07, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Viral-Associated GN: Hepatitis B and Other Viral Infections
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Viral-Associated GN: Hepatitis B and Other Viral Infections
Warren L. Kupin
CJASN Sep 2017, 12 (9) 1529-1533; DOI: 10.2215/CJN.09180816

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Viral-Associated GN: Hepatitis B and Other Viral Infections
Warren L. Kupin
CJASN Sep 2017, 12 (9) 1529-1533; DOI: 10.2215/CJN.09180816
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • HBV
    • Membranous Nephropathy
    • MPGN
    • Treatment
    • Additional HBV-Associated Glomerular Lesions
    • Acute and Subacute Viral-Induced GN
    • cFSGS
    • Viral-Induced De novo and Clinical Relapse of MC Disease
    • Summary
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Thrombotic Microangiopathy and the Kidney
  • Dysproteinemias and Glomerular Disease
  • Diabetic Kidney Disease
Show more Glomerular Diseases: Update for the Clinician

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Related Content

  • Glomerular Disease Series Collection (PDF)

Keywords

  • Viral-Associated Glomerulonephritis
  • Hepatitis B virus
  • glomerular disease
  • Antigen-Antibody Complex
  • antiviral agents
  • Carrier State
  • Coinfection
  • cytomegalovirus
  • Dengue
  • glomerulonephritis
  • HIV Infections
  • Hantavirus
  • Hepatitis C
  • Herpesvirus 4
  • human
  • humans
  • Immune Complex Diseases
  • immune system
  • Parvovirus
  • prevalence
  • Semantics
  • Streptococcal Infections

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire